Literature DB >> 27859766

Structural and molecular analysis of a protective epitope of Lyme disease antigen OspA and antibody interactions.

Shivender Shandilya1, Nese Kurt Yilmaz1, Andrew Sadowski2, Ejemel Monir2, Zachary A Schiller2, William D Thomas2, Mark S Klempner2, Celia A Schiffer1, Yang Wang2.   

Abstract

The murine monoclonal antibody LA-2 recognizes a clinically protective epitope on outer surface protein (OspA) of Borrelia burgdorferi, the causative agent of Lyme disease in North America. Human antibody equivalence to LA-2 is the best serologic correlate of protective antibody responses following OspA vaccination. Understanding the structural and functional basis of the LA-2 protective epitope is important for developing OspA-based vaccines and discovering prophylactic antibodies against Lyme disease. Here, we present a detailed structure-based analysis of the LA-2/OspA interaction interface and identification of residues mediating antibody recognition. Mutations were introduced into both OspA and LA-2 on the basis of computational predictions on the crystal structure of the complex and experimentally tested for in vitro binding and borreliacidal activity. We find that Y32 and H49 on the LA-2 light chain, N52 on the LA-2 heavy chain and residues A208, N228 and N251 on OspA were the key constituents of OspA/LA-2 interface. These results reveal specific residues that may be exploited to modulate recognition of the protective epitope of OspA and have implications for developing prophylactic passive antibodies.
Copyright © 2016 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Lyme disease; antibody; molecular interactions; mutations; protein structure; protein-protein; structural analysis; vaccine design

Mesh:

Substances:

Year:  2016        PMID: 27859766      PMCID: PMC5383521          DOI: 10.1002/jmr.2595

Source DB:  PubMed          Journal:  J Mol Recognit        ISSN: 0952-3499            Impact factor:   2.137


  17 in total

1.  Alternative vaccination schedules (0, 1, and 6 months versus 0, 1, and 12 months) for a recombinant OspA Lyme disease vaccine.

Authors:  C Van Hoecke; E Lebacq; J Beran; D Parenti
Journal:  Clin Infect Dis       Date:  1999-06       Impact factor: 9.079

2.  A hierarchical approach to all-atom protein loop prediction.

Authors:  Matthew P Jacobson; David L Pincus; Chaya S Rapp; Tyler J F Day; Barry Honig; David E Shaw; Richard A Friesner
Journal:  Proteins       Date:  2004-05-01

Review 3.  Vaccines against Lyme disease: What happened and what lessons can we learn?

Authors:  Gregory A Poland
Journal:  Clin Infect Dis       Date:  2011-02       Impact factor: 9.079

4.  What role do surfaces play in GB models? A new-generation of surface-generalized born model based on a novel gaussian surface for biomolecules.

Authors:  Zhiyun Yu; Matthew P Jacobson; Richard A Friesner
Journal:  J Comput Chem       Date:  2006-01-15       Impact factor: 3.376

5.  Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.

Authors:  W T Golde; J Piesman; M C Dolan; M Kramer; P Hauser; Y Lobet; C Capiau; P Desmons; P Voet; D Dearwester; J C Frantz
Journal:  Infect Immun       Date:  1997-03       Impact factor: 3.441

6.  Antibody structure determination using a combination of homology modeling, energy-based refinement, and loop prediction.

Authors:  Kai Zhu; Tyler Day; Dora Warshaviak; Colleen Murrett; Richard Friesner; David Pearlman
Journal:  Proteins       Date:  2014-04-16

Review 7.  Lyme borreliosis.

Authors:  Gerold Stanek; Gary P Wormser; Jeremy Gray; Franc Strle
Journal:  Lancet       Date:  2011-09-06       Impact factor: 79.321

8.  Structural identification of a key protective B-cell epitope in Lyme disease antigen OspA.

Authors:  W Ding; X Huang; X Yang; J J Dunn; B J Luft; S Koide; C L Lawson
Journal:  J Mol Biol       Date:  2000-10-06       Impact factor: 5.469

9.  HIV-1 Protease and Substrate Coevolution Validates the Substrate Envelope As the Substrate Recognition Pattern.

Authors:  Ayşegül Ozen; Türkan Haliloğlu; Celia A Schiffer
Journal:  J Chem Theory Comput       Date:  2012-02-14       Impact factor: 6.006

10.  Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2.

Authors:  B J Johnson; S L Sviat; C M Happ; J J Dunn; J C Frantz; L W Mayer; J Piesman
Journal:  Vaccine       Date:  1995-08       Impact factor: 3.641

View more
  4 in total

1.  Broadly Protective Multivalent OspA Vaccine against Lyme Borreliosis, Developed Based on Surface Shaping of the C-Terminal Fragment.

Authors:  Abhijeet Nayak; Wolfgang Schüler; Stefan Seidel; Ivan Gomez; Andreas Meinke; Pär Comstedt; Urban Lundberg
Journal:  Infect Immun       Date:  2020-03-23       Impact factor: 3.441

2.  Delineating Surface Epitopes of Lyme Disease Pathogen Targeted by Highly Protective Antibodies of New Zealand White Rabbits.

Authors:  Artem S Rogovskyy; Salvador Eugenio C Caoili; Yurij Ionov; Helen Piontkivska; Pavel Skums; Viachaslau Tsyvina; Alex Zelikovsky; Suryakant D Waghela
Journal:  Infect Immun       Date:  2019-07-23       Impact factor: 3.441

3.  Identification of Surface Epitopes Associated with Protection against Highly Immune-Evasive VlsE-Expressing Lyme Disease Spirochetes.

Authors:  Maliha Batool; Salvador Eugenio C Caoili; Lawrence J Dangott; Ekaterina Gerasimov; Yurij Ionov; Helen Piontkivska; Alex Zelikovsky; Suryakant D Waghela; Artem S Rogovskyy
Journal:  Infect Immun       Date:  2018-07-23       Impact factor: 3.441

4.  Human and Veterinary Vaccines for Lyme Disease.

Authors:  Nathaniel S O'Bier; Amanda L Hatke; Andrew C Camire; Richard T Marconi
Journal:  Curr Issues Mol Biol       Date:  2020-12-08       Impact factor: 2.081

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.